Irabelle Labomarel
Research Support Technician, November 2025 - Present
Leveraging Irabelle's background in immunotherapy, along with industry experience in immune cell and gene therapies and strong interest in drug delivery technologies, they are currently focused on the preclinical development of novel antibody-drug conjugates (ADCs) to target follicular lymphoma. Irabelle's goal is to characterize the pharmacodynamic and kinetic responses to cytotoxic payloads in ADCs.
Outside of work, Irabelle enjoys anthropology documentaries and podcasts, playing a mix of solitaire and mahjong, and planning their next trek.
